Lexaria Bioscience (CSE:LXX-OTCQX:LXRP) CEO Chris Bunka joined Steve Darling from Proactive Investors Vancouver to talk about Lexaria's new partnership with U.S. tobacco giant Altria.
Altria will fund a milestone-based research & development program in exchange for a minority equity interest in Lexaria Nicotine. Altria will provide initial funding of US$1 million, with the option for additional funding of up to US$12 million.
CSE:LXX
Market: CSE
Market Cap: $52.47 m
Follow
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Lexaria Bioscience Corp. named herein, including the promotion by the Company of Lexaria Bioscience Corp. in any Content on the Site, the...
FOR OUR FULL DISCLAIMER CLICK HEREMost read
Buds & Duds: Cannabis stocks hold steady; Lexaria rises on amended agreement...
The North American Marijuana Index, which tracks the top cannabis stocks in the US and Canada, inched 0.2% higher at 122.9 points. Elsewhere, the OTCQX Cannabis index lost 0.2% to 489.3 points. Buds today are Lexaria Bioscience Corp (CSE:LXX) (OTCMKTS:LXRP), Curaleaf Holdings Inc...
1 week, 5 days ago
2 min read
Prev article
3 min read
